Shopping Cart
Remove All
Your shopping cart is currently empty
Nitrendipine
Copy Product Info
🥰Excellent
Catalog No. T0119Cas No. 39562-70-4
Alias Bayotensin, BAY-E-5009
Nitrendipine (BAY-E-5009) is a calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
Nitrendipine
Copy Product Info🥰Excellent
Purity: 99.55%
Catalog No. T0119Alias Bayotensin, BAY-E-5009Cas No. 39562-70-4
Nitrendipine (BAY-E-5009) is a calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | $32 | In Stock | In Stock | |
| 25 mg | $50 | In Stock | In Stock | |
| 50 mg | $65 | In Stock | In Stock | |
| 100 mg | $122 | In Stock | In Stock | |
| 200 mg | $185 | In Stock | In Stock | |
| 500 mg | $297 | In Stock | In Stock | |
| 1 g | $459 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $50 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.55%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Nitrendipine AI Summary
Nitrendipine exhibits a wide range of bioactivities across multiple biological systems and potential therapeutic areas. It demonstrates significant inhibitory effects on calcium channels, particularly the L-type calcium channels with extremely low IC50 values (as low as 0.35 nM). This suggests potent activity as a calcium channel blocker, which translates to potential vasorelaxant properties in vascular tissues, evidenced by a reported IC50 of 1.0 nM in rabbit thoracic aorta and EC50 of 30.0 nM in rat endothelium-denuded thoracic aortic rings. Additionally, Nitrendipine shows significant antihypertensive effects in SHR rats, reducing both systolic and diastolic blood pressure.
In hepatic metabolism, Nitrendipine inhibits cytochrome P-450 enzymes, with substantial inhibition rates reported, such as 83.0% inhibition on human liver microsomes. This suggests potential interactions affecting drug metabolism. The compound also exhibits notable partition characteristics (CLogP of 3.16 and logD of 0.97), indicating moderate lipophilicity and ability to permeate cellular membranes, though it has low permeability across Caco-2 cells.
While Nitrendipine effectively inhibits sodium channels and shows an antifungal effect, it also exhibits moderate to weak activity against adenosine receptors and displays diverse bioactivity against Plasmodium falciparum, suggesting antimalarial potential. The compound shows a broad range of inhibitory effects on other targets, including the SARS-CoV-2 virus and various transporters and enzymes within cellular systems, highlighted by high clearance rates in hepatic metabolism and significant protein binding properties.
However, observations of moderate liver toxicity and potential nephrotoxic effects highlight the need for further safety evaluations. Additionally, the compound's low oral bioavailability suggests limitations in its systemic availability when administered orally.
Overall, Nitrendipine demonstrates a rich pharmacological profile with significant activities in modulating calcium channels, cytochrome P-450 enzymes, antiviral properties against SARS-CoV-2, as well as potential cardiovascular effects, meriting further investigation for therapeutic development while considering safety and bioavailability aspects..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Nitrendipine (BAY-E-5009) is a calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive. |
| Targets&IC50 | Ca2+ channel:95 nM |
| Synonyms | Bayotensin, BAY-E-5009 |
| Molecular Weight | 360.36 |
| Formula | C18H20N2O6 |
| Cas No. | 39562-70-4 |
| Smiles | C(OCC)(=O)C=1C(C(C(OC)=O)=C(C)NC1C)C2=CC(N(=O)=O)=CC=C2 |
| Relative Density. | 1.3595 g/cm3 (Estimated) |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (124.88 mM), Sonication is recommended.  H2O: < 1 mg/mL (insoluble or slightly soluble) Ethanol: < 1 mg/mL (insoluble or slightly soluble) | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.55 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Nitrendipine | purchase Nitrendipine | Nitrendipine cost | order Nitrendipine | Nitrendipine chemical structure | Nitrendipine formula | Nitrendipine molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.